Incannex Healthcare: On January 24, 2024, Incannex Healthcare Inc. Announced That It Has Commenced Dosing In The Phase 2 Clinical Trial To Assess The Safety And Efficacy Of Proprietary Combination Drug Candidate Ihl675a In Patients With Rheumatoid Arthiritis. Further Information Is Included In The Press Release Attached As Exhibit 99.1 Hereto, Which Is Incorporated By Reference Into This Item 8.01, Financial Statements And Exhibits
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameIncannex Healthcare Limited (formerly Impression Healthcare Limited)
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









